Statements (24)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
|
| gptkbp:approvalYear |
2017
|
| gptkbp:ATCCode |
A10BK04
|
| gptkbp:combinationProduct |
gptkb:Segluromet
gptkb:Steglujan |
| gptkbp:contraindication |
severe renal impairment
|
| gptkbp:drugClass |
SGLT2 inhibitor
|
| gptkbp:eliminationHalfLife |
about 16 hours
|
| gptkbp:form |
5 mg
15 mg |
| gptkbp:genericName |
gptkb:ertugliflozin
|
| https://www.w3.org/2000/01/rdf-schema#label |
Steglatro
|
| gptkbp:legalStatus |
prescription only
|
| gptkbp:manufacturer |
gptkb:Pfizer
gptkb:Merck_&_Co. |
| gptkbp:mechanismOfAction |
inhibits SGLT2 in the proximal renal tubules
|
| gptkbp:pregnancyCategory |
Not recommended
|
| gptkbp:routeOfAdministration |
oral
|
| gptkbp:sideEffect |
urinary tract infection
genital mycotic infection increased urination |
| gptkbp:usedFor |
gptkb:type_2_diabetes_mellitus
|
| gptkbp:bfsParent |
gptkb:Merck_&_Co.
|
| gptkbp:bfsLayer |
4
|